Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record.

Clindamycin, Cephalosporins, Fluoroquinolones, and Clostridium difficile–Associated Diarrhea: This Is an Antimicrobial Resistance Problem

Gerding, Dale N.·2004·Clinical Infectious Diseases

Abstract

Clostridium difficile–associated diarrhea (CDAD) is a unique hospital infection that occurs almost entirely in patients who have received previous antimicrobial treatment. Although not conclusively proven, the normal gastrointestinal flora is presumably disrupted by antimicrobials, which, in turn, enables ingested spores of toxigenic C. difficile to colonize the colon, produce toxins, and cause CDAD. Epidemiologic evidence suggests that specific antimicrobials and classes of antimicrobials are not created equal in terms of CDAD risk [1]. Two risks for CDAD are of interest because of how they relate to antimicrobial use: the relative risk of CDAD associated with use of a specific antimicrobial, and the attributable risk of CDAD in a particular population. Attributable risk incorporates both the relative risk of an antimicrobial and the frequency with which that drug is used in the population. Clindamycin was the highest-risk agent for CDAD in the 1970s, but its use has decreased in US and European hospitals, with a resultant reduction in attributable risk of antibiotic-associated diarrhea and CDAD [2]. By the late 1980s and through the 1990s, cephalosporin antimicrobials, particularly those of the second and third generation, such as cefuroxime, cefotaxime, ceftazidime, and ceftriaxone, had become the agents with the highest relative risk and highest attributable risk of CDAD because of their frequent use in hospitals [1]. The risk of antimicrobial-associated CDAD is increased if C. difficile is resistant to the antimicrobial [3]. For clindamycin, C. difficile resistance is variable, and risk of CDAD associated with a clindamycin-resistant organism is increased in patients receiving clindamycin [3]. For the third-generation cephalosporins, C. difficile resistance is universal, and presumably any toxigenic C. difficile organism is capable of causing CDAD during cephalosporin administration. The good news has been that CDAD rates have markedly decreased when the use of clindamycin or third-generation cephalosporins has been reduced in hospitals where these agents were associated with high CDAD rates [3, 4]. More recently, the saga of CDAD risk and antimicrobial use has been extended to the fluoroquinolone class, as shown by Gaynes et al. [5] in this issue of Clinical Infectious Diseases and by others [6–8]. Fluoroquinolones had been considered relatively low-risk agents for CDAD on the basis of a number of observations with regard to ciprofloxacin that included poor anaerobic activity, failure of fecal emulsions treated with ciprofloxacin to support growth of C. difficile in vitro (compared with clindamycin-treated emulsions), and lack of observed CDAD or C. difficile colonization in a population of 213 patients treated with ciprofloxacin monotherapy [9]. Ciprofloxacin has been used in the United States since 1988, but it was not until 2001 that a clinical case-control study showed the association between fluoroquinolone use and risk of CDAD [6]. The study was conducted in 1998 and used 2 different sets of control subjects (the first was matched for age, sex, and admission date, and the second was matched for duration of hospital stay). Multivariable analysis implicated use of ciprofloxacin as a risk factor for CDAD for the 2 control groups (OR, 5.5 [95% CI, 1.2–24.8] and 9.5 [95% CI, 1.01–88.4], respectively) [6]. A very large matched case-control study of 199 patients conducted in Pittsburgh during 2000–2001 showed a significant association between CDAD and levofloxacin use (OR, 2.2; 95% CI, 1.3–3.7), as well as significant associations between CDAD and use of clindamycin, ceftriaxone, and cefepime [7]. Of interest, in this study, more patients (n = 118) received levofloxacin than received all of the other 3 high-risk antibiotics combined (n = 98), suggesting a high attributable CDAD risk for levofloxacin [7]. The authors collected C. difficile isolates and found high-level resistance to levofloxacin, ofloxacin, moxifloxacin, gatifloxacin, and ciprofloxacin in 90% of the isolates tested [7]. Restriction endonuclease typing of isolates revealed that 51% of the isolates were of 3 major types, and 2 of these types differed by only a single band. One additional case-control study of CDAD, done in 2001, involved inpatients in 4 Veterans Affairs Medical Centers [8]. Thirty patients with CDAD and 60 control subjects were compared in a multivariable analysis, and the only significant CDAD risk factor identified was fluoroquinolone use (OR, 12.7; 95% CI, 2.6–61.6) [8]. The fluoroquinolones used were levofloxacin (60% of subjects), ciprofloxacin (15%), and gatifloxacin (15%). The study by Gaynes et al. [5] is particularly noteworthy for several reasons. Foremost is the fact that it demonstrates a difference in CDAD risk during periods when 2 different but very similar fluoroquinolones (levofloxacin and gatifloxacin) were in use, and it demonstrates that the high risk of CDAD observed with gatifloxacin can be reduced b

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/382084

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Authors
Gerding, D. N.
Venue
Clinical Infectious Diseases
Published
2004-03
Volume
38
Issue
5
Pages
646-648
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2167717276
Cited by
175
References
0
FWCI
10.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clindamycin, Cephalosporins, Fluoroquinolones, and Clostridium difficile–Associated Diarrhea: This Is an Antimicrobial Resistance Problem. https://app.cochat.ai/papers/10.1086/382084
The paper
Gerding, D. N. (2004). Clindamycin, Cephalosporins, Fluoroquinolones, and Clostridium difficile–Associated Diarrhea: This Is an Antimicrobial Resistance Problem. Clinical Infectious Diseases. https://doi.org/10.1086/382084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.